A cross-sectional and longitudinal observational study of cognitive decline between the symptomatic AD patients and cognitively normal controls proved that the CSF levels of Ng can develop the diagnosis and prognosis for early symptomatic AD that is comparable with other CSF biomarkers of AD (Tarawneh et al., 2016). This evidence concerns the gene NRGN and Alzheimer disease.